21 results about "Immuno therapy" patented technology

Disclosed herein are methods of using OX40 as a biomarker for predicting clinical sensitivity and therapeutic response of subjects having cancer to treatment with immunotherapeutic agents, and methods of using OX40 as a biomarker for selecting patient population for cancer treatment with immunotherapeutic agents. Disclosed herein are also methods of treating OX40-expressing cancers using immunotherapeutic agents. Further provided herein are kit for predicting the responsiveness of a subject having cancer to treatment with immunotherapeutic agents.

The present invention relates to a method for selecting a patient group predicted to respond to immunotherapy cancer treatment. According to the method of the present invention, it is possible to distinguish, in advance, between a patient group that is likely to respond to anti-TIGIT and / or anti-IL-6 immunotherapeutic agents and a patient group that is unlikely to respond to same, enabling effective treatment to be performed, and thus the method is expected to be widely applicable in the medical field.

Aspects of the present disclosure are directed to methods and compositions for diagnosing and / or treating a subject having cancer. Certain aspects relate to treatment with a cancer therapy and a YTHDF2 inhibitor or a pharmaceutical composition comprising a cancer therapy and a YTHDF2 inhibitor. In some aspects, the YTHDF2 inhibitor includes an oligonucleotide targeting YTHDF2 mRNA or a small molecule inhibitor of YTHDF2. In some aspects, a subject has been determined to have or to have had resistance to a previous cancer treatment, such as radiotherapy and / or immunotherapy.

Methods for targeting a tumor antigen for immunotherapy based on HLA allele type and the mutations present in the tumor antigen are presented. A patient's HLA allele type and a tumor antigen derived from a mutation in cancer driver gene can be matched with a majority allele type having a minimum affinity to the same tumor antigen or with those of a plurality of patients with a history of cancer treatment. Upon matching, a cancer treatment against the tumor antigen can be selected and administered to the patient to achieve a desired effect.

The present invention relates to combinations of host cells expression antigen binding proteins that specifically bind to a tumor expressed Preferentially Expressed Antigen of Melanoma (PRAME) antigenic peptide in a complex with MHC, and mRNAs encoding PRAME antigenic peptides. The invention further relates to combined TCR-T / mRNA therapy employing said mRNAs and host cells. In particular, a combined TCR-T / mRNA therapy is provided for use in cancer treatment.

This invention provides compositions for drug delivery in cancer treatment and immunotherapy. [Solution] A composition is provided comprising polymer gelatin, silicate nanoparticles, and a therapeutic agent having a molecular weight of less than 1000 daltons, wherein the gelatin, the silicate nanoparticles, and the therapeutic agent form a shear-thinning hydrogel.

Provided are a combined therapy of photodynamic therapy and immunological therapy, comprising the combined administration of a porphyrin dimer salt-based photosensitizer and an immune checkpoint inhibitor, and the use thereof in treatment of recurrent and / or metastatic cancers, in particular esophageal cancer.

Disclosed herein is the use of a copper chelating agent or an agent capable of inducing a copper chelating agent for the treatment of cancer, in particular for increasing the efficiency of an immunotherapy for the treatment of cancer. Disclosed herein are methods of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a copper chelating agent or a copper chelating agent inducer in combination with a therapeutically effective amount of an anti-cancer immunotherapeutic agent. Also disclosed herein are kits or combinations and compositions comprising a copper chelating agent or a copper chelating agent inducer and an anti-cancer immunotherapeutic agent, and uses thereof for the treatment of cancer.

The present disclosure relates to methods of treating cancer in a subject by administering to the subject effective amounts of an anti-CCR8 antibody, a chemotherapeutic agent (e.g., cisplatin, gemcitabine, docetaxel), and a PD1 inhibitor or a PD-L1 inhibitor. In some embodiments, the chemotherapeutic agent is administered at a lower dose than in a standard of care chemotherapy regimen that does not include the anti-CCR8 antibody. In some embodiments, the chemotherapeutic agents are co-administered at a lower dose than in a standard of care chemotherapy regimen that does not include the anti-CCR8 antibody.

The present invention relates to a method for diagnosing whether anticancer therapy will exhibit responsiveness in a particular patient. The anticancer therapy may include chemotherapy or cancer immunotherapy. Specifically, whether anticancer therapy will exhibit responsiveness in a particular patient can be confirmed through a TCTP level in the plasma of the corresponding patient. In such an aspect, the present invention also relates to use of plasma TCTP as a biomarker indicative of responsiveness to anticancer therapy.

This invention relates to biomarkers for predicting the therapeutic responsiveness of cancer patients to immune checkpoint inhibitors. Since gene signatures and gene markers based on a specific pattern demonstrate significantly superior predictive power regarding the therapeutic responsiveness of cancer patients to immuno-anticancer drugs, it is possible to select patient groups predicted to show a therapeutic effect and perform appropriate treatment, thereby reducing patient suffering and costs.

The present invention relates to an inverse opal (IOPAL) hydrogel formed with poly(ethylene)glycol (PEG) covalently bonded to heparin (Hep) and having a storage shear modulus (G') between 2.5 and 4 kPa. Said hydrogel with improved mechanical and structural properties has demonstrated to be highly effective in CAR T cell expression and, therefore, in CAR T adoptive cell therapy.

An image depicting a tissue sample is received. One or more tissue compartments present in the image of the tissue sample are identified including by generating a compartment map identifying pixels in the image depicting the tissue compartments. One or more cells present in the image of the tissue sample are identified including by generating a cell map identifying pixels in the image depicting the cells. A density-based pathology signature for the image of the tissue sample is determined based on the compartment map and the cell map. The density-based pathology signature includes a density of each cell type present in the one or more tissue compartments. A response computation model is applied to determine, based on the density-based pathology signature, a predictive output indicative of a likelihood of a patient associated with the tissue sample responding to an anticancer therapy such as immunotherapy.

The invention relates to an in vitro method for predicting the early progression of cancer in a subject undergoing immunotherapy. This method comprises determining, in a blood sample isolated from the subject, the total concentration of circulating cell-free DNA and the concentration of large circulating cell-free DNA fragments, combining these data in a mathematical function to obtain a score, and comparing this score to a predetermined reference value. It concludes that the subject exhibits early progression during immunotherapy treatment when the score obtained is less than or equal to the reference value.

The present invention concerns improved methods and compositions for neoadjuvant use of antibody-drug conjugates (ADCs) in cancer therapy, preferably ADCs comprising an anthracycline or camptothecin, more preferably SN-38 or pro-2-pyrrolinodoxorubicin (P2PDox). The ADC is administered as a neoadjuvant, prior to treatment with a standard anti-cancer therapy such as surgery, radiation therapy, chemotherapy, or immunotherapy. Neoadjuvant use of the ADC substantially improves the efficacy of standard anti-cancer therapy and may debulk a primary tumor or eliminate micrometasteses. In most preferred embodiments, neoadjuvant ADC in combination with a standard anti-cancer therapy is successful in treating cancers that are resistant to standard treatments, such as triple-negative breast cancer (TNBC).

This invention relates to an oral immunotherapy (OIT) composition comprising granules that contain an allergenic protein, such as peanut protein, along with a humectant, such as trehalose, and a binder, such as hypromellose. The composition may further comprise a filler, such as mannitol and a lubricant, such as stearic acid. OIT compositions, methods of preparing OIT compositions and methods of treatment of food allergy using OIT compositions are provided.

Shear-thinning biomaterial technology offers enables polymers and drugs loaded inside such polymers to be easily delivered directly through catheters into target area for use, for example, in cancer therapy and immunotherapy. When a force above a certain threshold is applied to inject such materials, they “thin” and behaves as a semi-solid, allowing the material to readily flow through a catheter. When the force is removed, the material instantly becomes a soft solid with significant cohesive properties that prevent it from dislodging or breaking up. We have developed novel shear-thinning biomaterials using spherical silica nanoparticles and gelatin-based polymers. Rheological tests confirm that these materials have excellent shear-thinning properties and further have improved material properties (e.g. improved stability profiles) as compared conventional materials available to medical professionals.

The invention relates to the technical field of anti-tumor, in particular to a manganese boride photo-thermal nano-particle and a preparation method and application thereof. According to the invention, beta-cyclodextrin and manganese boride are used as raw materials, and an ICD inducer MnB-beta-CD with a photothermal effect is synthesized through a high-temperature carbonization method; the ICD inducer can promote the collection of dendritic cells (DCs) and enhance the cross excitation of anti-tumor effect T cells under the irradiation of near-infrared light. In addition, the ICD inducer also has good biological safety, and an immunotherapy and a photothermal therapy are integrated on the same platform.

The application provides a kind of drug composition in the preparation for the application of the drug for the maintenance treatment of disease control ES-SCLC after first-line chemotherapy, belong to the biomedicine technical field.The drug composition is carimab and apatinib.The application finds that carimab is combined with apatinib as maintenance treatment, shows encouraging efficacy and acceptable safety in ES-SCLC patient who is not in progress after first-line chemotherapy, the median overall survival (OS) is 25.00 months, and the 12-month OS rate is 71.4%.This strategy of simultaneously targeting PD-1 and VEGFR2 provides a novel and reasonable solution for extending the disease control period in malignant tumors with limited treatment options after induction therapy, not only solves the key needs of ES-SCLC patients for more effective maintenance treatment, but also provides important insights into the biological principles of anti-angiogenic therapy combined with immunotherapy.

A procedure for the destruction of cancer cells based on the use of magnetically coated nanoparticles (NPs), preferably coated with biocompatible molecules, which are taken up by cells through endocytosis or cell membrane transport proteins, and the application, preferably, of variable electromagnetic fields using device (1). These fields can be modified in frequency, intensity, and duration using a data input device (10), and these parameters are displayed using display devices (8) (9). This generates a magneto-mechanical process that agitates the nanoparticles inside the cell and causes their destruction, without the need for chemotherapy, radiotherapy, immunotherapies, heat treatments, surgery, or any other intervention. This procedure is applicable to any type of tumor, regardless of size, shape, or location in the body.